The difficult quest for data on "vanishing" vaccine-preventable infections in Europe: The case of measles in Flanders (Belgium)

Vaccine

Volumn 20, Issue 29-30, 2002, Pages 3551-3559

  Beutels, Ph ^a   Van Damme, P ^a   Van Casteren, V ^b   Gay, N J ^c   De Schrijver, K ^d   Meheus, A ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d Ministry of the Flemish Community   (Belgium)

Author keywords

Cost; Measles; Vaccination

Indexed keywords

MEASLES VACCINE;

ADOLESCENT; ADULT; ARTICLE; BELGIUM; CHILD; CONTROLLED STUDY; COST; ENCEPHALITIS; EPIDEMIOLOGICAL DATA; EUROPE; GROUPS BY AGE; HEALTH CARE COST; HUMAN; IMMUNITY; INFANT; LONG TERM CARE; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MEASLES; MORBIDITY; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; RELIABILITY; SCHOOL CHILD; SEROPREVALENCE; SUBACUTE SCLEROSING PANENCEPHALITIS; VACCINATION;

ADOLESCENT; ADULT; BELGIUM; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; HEALTH CARE COSTS; HUMANS; INCIDENCE; MEASLES; MEASLES VACCINE; VACCINATION;

EID: 0037019918     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00335-3     Document Type: Article

References (26)

1. World Health Organisation, World Health Report 2001.
2. Payne D. Ireland's measles outbreak kills two. Br Med. J. 321(7255):2000;197B.
3. Anderson RM, May RM, Infectious diseases of humans - dynamics and control. Oxford: Oxford University Press, 1991.
4. WHO Europe. Measles: a strategic framework for the elimination of measles in the European Region. WHO Copenhagen, 1999.
5. Anderson R, Nokes DJ, Mathematical models of transmission and control. In: Holland WW, Detels R, Knox EG, editors. Oxford textbook of public health. Oxford: Oxford University Press; 1996, pp. 689-719.
6. Orenstein W.A., Bernier R.H., Dondero T.J.et al. Field evaluation of vaccine efficacy. Bull World Health Organ. 63(6):1985;1055-1068.
7. Ministry of the Flemish Community. Registration of the School Health Centres 1993-1994 and 1994-1995, November 1996 [in Dutch].
8. Swennen B., Van Damme P., Vellinga A., Coppieters Y., Depoorter A.M. Analysis of factors influencing vaccine uptake: perspectives from Belgium. Vaccine. 20(Suppl 1):2001;S5-S7.
9. Vellinga A., Depoorter A.M., Van Damme P. Vaccination coverage estimates by EPI cluster sampling survey of children (18-24 months) in Flanders. Belgium Acta Paediatr. 91(5):2002;599-603.
10. Babad H.R., Nokes D.J., Gay N.J., Miller E., Morgan-Capner P., Anderson R.M. Predicting the impact of measles vaccination in England and Wales: model validation and analysis of policy options. Epidemiol Infect. 114(2):1995;319-344.
11. Beutels Ph, Gay NJ, Economic evaluation of options for measles vaccination strategy in a hypothetical western European country. Working paper.
12. Miller CL, Severity of notified measles. Br Med J 1978;(1):1253-5.
13. Miller C., Farrington C.P., Harbert K. The epidemiology of subacute sclerosing panencephalitis in England and Wales 1970-1989. Int. J. Epidemiol. 21(5):1992;998-1006.
14. Miller D.L. Frequency of complications of measles, 1963. Report on a National Inquiry by the Public Health Laboratory Service in collaboration with the society of medical officers of health. Br Med J. 2:1964;75-78.
15. CDC. Measles encephalitis - United States 1962-1979. MMWR 1981;31:217-24.
16. Feigin RD, Cherry JD, Textbook of pediatric infectious diseases. 4th ed. Philadelphia: Saunders; 1998.
17. Bond van Grote en Jonge Gezinnen. Children: an expensive affair? June 1994 [in Dutch].
18. Flemish fund for social integration of persons with a handicap, 1999.
19. Pelletier L., Chung P., Duclos P., Manga P., Scott J. A benefit-cost analysis of two-dose measles immunization in Canada. Vaccine. 16(9/10):1998;989-996.
20. Taracena del Pinal B., Monton J.L., Cristobal P., Gonzalez F., Casas J. Contribución al estudio de costos del sarampión en España. An Esp Pediatr. 19(5):1983;383-388.
21. McConnell W.W., Tohani V.K. Measles in the Southern Health Board - implications for resources. Br Med J. 289(6440):1984;293-296.
22. Duclos P., Ward B.J. Measles vaccines: a review of adverse events. Drug Saf. 19(6):1998;435-454.
23. Weinstein M.C., Siegel J.E., Garber A.M. Productivity costs, time costs and health related quality of life: a response to the Erasmus group. Health Econ. 6:1997;505-510.
24. Koopmanschap M.A., Rutten F.F.H. Indirect costs in economic studies: confronting the confusion. PharmacoEconomics. 4:1993;446-454.
25. Beutels P, Van Damme P, Van Doorslaer E, Program evaluation of universal varicella vaccination in Belgium, ESOC-report no. 36. Antwerp: Antwerp University; 2000. 39 p.
26. De Schrijver K. Outbreak of measles among adolescents, Belgium. Eurosurveillance. 1:1996;46-47.